Chapter 19. Diagnosis and Management of Acquired Bleeding Disorders: Vitamin K Antagonists
- Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
- Jeff Ginsberg MD, FRCPC Professor4,
- Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
- Ralph M. Meyer MD, FRCPC Director Professor7,8,
- Richard Lottenberg MD, FACP Professor9
Published Online: 4 FEB 2009
Copyright © 2008 Blackwell Publishing Ltd
How to Cite
Escobar, M. A. (2009) Diagnosis and Management of Acquired Bleeding Disorders: Vitamin K Antagonists, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch19
Division of Hematology, McMaster University, Hamilton, Ontario, Canada
St. Joseph's Hospital, Hamilton, Ontario, Canada
Department of Medicine, McMaster University, Hamilton, Canada
CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy
McMaster University, Hamilton, Canada
National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada
Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
- Published Online: 4 FEB 2009
- Published Print: 27 JUN 2008
Print ISBN: 9781405157476
Online ISBN: 9781444300857
- acquired bleeding disorders;
- length of therapy;
- actual risk of bleeding and use of vitamin K antagonists;
- cumulative incidence of major bleeding;
- role of subcutaneous vitamin K;
- recommended dose of oral Vitamin K;
- management of nonbleeding patient;
- management of bleeding patient;
- coagulopathy due to VKAs - common problem in outpatient clinics
This chapter contains sections titled:
What is the risk of bleeding with the use of vitamin K antagonists?
Can we calculate the actual risk of bleeding with the use of vitamin K antagonists?
What is the recommended management for bleeding due to vitamin K antagonists?
Is there a role for subcutaneous vitamin K?
What is the recommended dose of oral Vitamin K?